close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

206.89 +1.05 (+0.51%)
Streaming Delayed Price Updated: 1:11 PM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
News headline image
$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
RxSight Stock Sees Relative Strength Rating Rise To 91 ↗
On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91. 
Via Investor's Business Daily
News headline image
Why Quality-Oriented Investors Should Consider NYSE:RMD. ↗
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill
News headline image
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
From ResMed Inc.
Via GlobeNewswire
News headline image
NYSE:RMD may be ready to breakout. ↗
There are signs that NYSE:RMD may be ready to breakout. 
Via Chartmill
News headline image
Uncovering Dividend Opportunities with NYSE:RMD. ↗
Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing? 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $9,500 Today ↗
 
Via Benzinga
News headline image
ResMed's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? ↗
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
News headline image
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities ↗
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
News headline image
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $16,000 Today ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About ResMed ↗
 
Via Benzinga
News headline image
Looking Into ResMed's Recent Short Interest ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,600 Today ↗
 
Via Benzinga
News headline image
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Stock Market News From Amazon, Nike, McCormick, and More ↗
We also talk with author Nicola Twilley about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves." 
Via The Motley Fool
News headline image
Falling Knives: 3 Stocks Getting the Cold Shoulder From Analysts ↗
Uncover key insights on stocks with negative analyst sentiment, including major moves by Alphabet, Nike and ResMed. 
Via InvestorPlace
News headline image
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
Is NYSE:RMD a Good Fit for Dividend Investing? ↗
Uncovering Dividend Opportunities with RESMED INC (NYSE:RMD). 
Via Chartmill
News headline image
Beyond The Numbers: 6 Analysts Discuss ResMed Stock ↗
 
Via Benzinga
News headline image
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You? ↗
We also talk about weight loss drugs and sleep apnea, and other stock market news. 
Via The Motley Fool
News headline image
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
News headline image
Sound Investments: 3 Stocks to Buy for a Good Night’s Rest ↗
The safe stocks to buy for a good night’s rest aren’t the kind you’re thinking about. Nonetheless, they do make worthwhile investments. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why ResMed Shares Are Trading Lower Monday ↗
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatment of sleep apnea. 
Via Benzinga
News headline image
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday? ↗
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
News headline image
Stocks Mixed As Investors Take Big Tech Profits ↗
The major benchmarks are mixed today, as investors cycle out of the outperforming tech sector and buy into bank and energy stocks. 
Via Talk Markets
News headline image
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again ↗
Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.